rs1017861 — CHD7 CHD7 AIS susceptibility locus

CHD7 rs1017861 — A Chromatin Remodeler's Footprint on Spinal Architecture and Immune Tissue Development

CHD7¹¹ CHD7
chromodomain helicase DNA binding protein 7, an ATP-dependent chromatin remodeler encoded at chromosome 8q12.2 is best known for its catastrophic role in CHARGE syndrome²² CHARGE syndrome
a rare developmental disorder causing Coloboma, Heart defects, Atresia choanae, Retarded growth, Genital abnormalities, and Ear anomalies — caused by heterozygous CHD7 loss-of-function mutations. Rare mutations eliminate CHD7 function; common intronic variants like rs1017861 operate more subtly — modulating how the gene is expressed during critical developmental windows.

CHD7 is an essential regulator of neural crest cells³³ neural crest cells
a migratory embryonic cell population that gives rise to the peripheral nervous system, craniofacial skeleton, cardiac outflow tract, thymus, parathyroid glands, and inner ear. The thymus — and therefore much of the adaptive immune system's T-cell repertoire — develops from neural crest-derived pharyngeal pouch tissue under CHD7 control. This dual role in skeletal patterning and immune-system organogenesis places CHD7 in the innate and developmental immunity category alongside other genes whose structural contributions to the immune system matter as much as their direct immunological signalling.

The Mechanism

Rs1017861 lies in intron 2 of CHD7 (NM_017780.4:c.-175+27072A>G, GRCh38 chr8:60,706,154). The intronic location suggests it acts as a regulatory variant — influencing CHD7 expression levels or splice-site usage in specific tissues during development — rather than altering the CHD7 protein sequence. Precise cis-eQTL data for rs1017861 have not been published, but the variant's location near exons 2-4, where disease-associated haplotypes cluster most strongly, places it within the same regulatory neighbourhood as the functional polymorphisms identified in the Gao 2007 fine-mapping study.

CHD7 remodels chromatin at enhancers active during paraxial mesoderm and neural crest differentiation. When CHD7 activity is perturbed — even subtly — the transcriptional programmes that pattern the axial skeleton, paraspinal musculature, inner ear, and thymus are altered. The result in common-variant carriers is not a structural birth defect but a quantitative shift in tissue patterning that, at the population level, predisposes to adolescent idiopathic scoliosis (AIS) and possibly to subtle immune-tissue variation.

The Evidence

The primary genetic association comes from Gao et al. 2007⁴⁴ Gao et al. 2007
CHD7 gene polymorphisms are associated with susceptibility to idiopathic scoliosis — Am J Hum Genet, a linkage and association study of 52 IS families that produced a multipoint LOD of 2.77 (p = 0.0028) for chromosome 8q12, with fine-mapping of 23 CHD7 SNPs identifying significant disease-associated haplotypes (p < 1×10⁻⁴) over exons 2-4. This was the first report naming CHD7 as an IS susceptibility gene.

Direct evidence for rs1017861 itself comes from Borysiak et al. 2020⁵⁵ Borysiak et al. 2020
CHD7 gene polymorphisms in female patients with idiopathic scoliosis — BMC Musculoskelet Disord, a Polish case-control study of 211 female AIS patients and 83 controls. The rs1017861 polymorphism showed statistically significant association with IS susceptibility (p < 0.01) and with curve severity and progression rate (p < 0.05). The authors conclude that CHD7 should be considered an IS-modifying factor.

Replication has been mixed. Tilley et al. 2013⁶⁶ Tilley et al. 2013 failed to replicate CHD7 association across 22 SNPs in 244 European-descent familial IS families (p > 0.01), highlighting that familial and sporadic IS may have different genetic architectures, and that replication across ethnicities and study designs is incomplete. A 2025 study (Dai et al., PMID 39206768) further found that rs1017861 does not significantly predict brace treatment outcome, suggesting the variant is relevant for susceptibility rather than disease course once AIS is established.

The evidence level for this variant is therefore moderate — statistically significant association in at least one case-control study with plausible biological mechanism, but inconsistent replication and absent population-level GWAS confirmation at genome-wide significance thresholds.

Practical Actions

The primary actionable consequence is heightened awareness of scoliosis risk during adolescent growth. AIS emerges during the pubertal growth spurt (ages 10-16), has a strong female predominance, and responds well to bracing when detected at curves of 20-40°. GG carriers, particularly adolescent girls, benefit most from systematic spinal assessment during this window.

CHD7's role in neural crest-derived immune tissue development — especially thymus organogenesis — also connects this variant to the innate-infection category. Carriers with a history of recurrent infections, unusual immune responses, or sensorineural hearing loss may have a developmental basis worth investigating, though direct immunological evidence for rs1017861 specifically is not yet published.

Interactions

CHD7 at 8q12 sits alongside other AIS susceptibility loci identified in recent GWAS. The most studied co-loci include rs1978060 (TBX1, 22q11.21) and rs10738445 (BNC2). Combined burden across multiple AIS susceptibility variants predicts risk better than any single locus, though specific compound action data for the CHD7 + TBX1 or CHD7 + BNC2 combinations are not yet published. The developmental overlap between CHD7 and TBX1 — both are essential regulators of pharyngeal arch derivatives including the thymus, inner ear, and paraspinal tissues — makes a compound interaction biologically plausible.